WO2004060381A1 - Peau de lapin comprenant une substance bioactive et son utilisation - Google Patents
Peau de lapin comprenant une substance bioactive et son utilisation Download PDFInfo
- Publication number
- WO2004060381A1 WO2004060381A1 PCT/CN2003/000923 CN0300923W WO2004060381A1 WO 2004060381 A1 WO2004060381 A1 WO 2004060381A1 CN 0300923 W CN0300923 W CN 0300923W WO 2004060381 A1 WO2004060381 A1 WO 2004060381A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rabbit
- skin
- rabbit skin
- rabbits
- strain
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
- A23J1/10—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from hair, feathers, horn, skins, leather, bones, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
- A61K39/285—Vaccinia virus or variola virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
Definitions
- the invention relates to a rabbit skin containing a biologically active substance and use thereof. Background technique
- the object of the present invention is to provide a rabbit skin containing an active substance with a high activity and a high yield, which can be used for preparing not only medicines but also health products.
- the rabbit skin of the present invention is prepared by the following method: Vaccination of rabbits with a vaccinia virus strain
- Vaccinia virus is a type of virus widely used in this century.
- Various strains of vaccinia virus can be used to prepare the rabbit skin of the present invention.
- the virus strains such as the vaccinia virus lister strain, Ikeda strain, Dairen strain, EM-63 strain, Temple of Heaven strain, LMC strain, Tashkent strain, Williamsport strain, New York City Board of Health strain.
- Lister strain, Ikeda strain, Dairen strain, and EM-63 strain are preferable, and Lister strain is most preferable.
- the virus used for vaccination can be purchased directly from the market, or it can be obtained by subculture of rabbits.
- the above-mentioned inoculation is suitable for subcutaneous inoculation. It is injected at a rate of 100 to 250 per 1.5 to 3 kg of rabbits, and each injection is 0.1 to 0.4 ml of a solution containing 10 6 to 10 9 viruses per ml.
- the rabbits used to prepare the rabbit skin of the present invention may be various rabbits, such as rabbits such as Japanese big-eared white rabbits, New Zealand white rabbits, Chinese local rabbits, blue purple rabbits, silver gray rabbits (Silver Fox) , Vienna rabbit, longhair rabbit, Himalayan albio rabbit, Pex rabbit, Belgian Hare, Lop, California Rabbit, Chekered
- Giant Danish white rabbit, West German longhair rabbit.
- Preferred are Japanese big-eared white rabbits, New Zealand white rabbits, Chinese native rabbits, and blue-violet rabbits, and most preferred are Japanese big-eared white rabbits.
- Good skin tissue acne refers to the obvious acne on the skin tissue, the color changes from ruddy to purplish red, the skin is thickened, and the subcutaneous and buttocks are edema.
- the method of sacrifice rabbit is cervical dislocation. Best practice
- Dry vaccinia lister strain of vaccinia virus Lister strain with PBS (-) solution 80 g of sodium chloride, 2 g of potassium chloride, 11.5 g of sodium dihydrogen phosphate, 2 g of potassium dihydrogen dihydrate, and inject water to 10 L) Dissolve and shake well.
- the needle was used to extract 0.4 liters and injected into the central inner layer of the testicles of known Japanese big-eared white rabbits.
- the neck was strongly broken and the scrotum was cut open to remove testicular connective tissue. Put the testicles cut into a special container with ice cubes, and then store them in an ultra-low temperature refrigerator at -80 ° C.
- EAGLE'S medium EAGLE's powder 9.4 g, 10% sodium bicarbonate 12.5-22.0 liters, glutamine 10 liters, injection Water (1 liter), mix, aliquot, freeze in an ultra-low temperature refrigerator at -80 ° C for 1 hour, and then take it out in a water box at 37 ° C to thaw. Then, perform low-temperature centrifugation (4 ° C, 3500rpm, 20 minutes). Divide into 10 ml each. This antigen secondary culture was stored in an ultra-low temperature refrigerator at -8 ° C.
- the acne is good, the color changes from ruddy to purplish red, the skin is thickened, there is edema under the skin, and the hips are edema obvious.
- Rabbits were sacrificed by cervical dislocation, and the crusts were completed within 15 minutes. Pack the rabbit skin in a plastic bag and save it immediately Store in a freezer at -18 ° C.
- the obtained rabbit skin weight was 349 grams, and its SART activity was 0.85 iu / g.
- the absorbance value in the angiotensin production inhibitory test is 0.07, and it has an angiotensin production inhibitory activity on the surface.
- Example 2 A vaccinia virus Ikeda strain and a New Zealand white rabbit were used to prepare an antigen secondary culture according to the method of Example 1.
- the acne is good, the color changes from ruddy to purplish red, the skin is thickened, there is edema under the skin, and the edema of the buttocks is obvious.
- Rabbits were sacrificed by pushing the neck off the white method, and the skin was finished within 15 minutes. Pack the rabbit skin in a plastic bag and store it in a freezer at -18 ° C immediately. The weight of the obtained rabbit skin was 302 g, and its SART activity was 0.60 iu / g.
- the absorbance value is 0.1, and it has an angiotensin production inhibitory activity on the surface.
- the acne is good, the color changes from ruddy to purplish red, the skin is thickened, there is edema under the skin, and the hips are edema obvious.
- Rabbits were sacrificed by pushing the neck off the white method, and skin harvesting was completed within 15 minutes. Pack the rabbit skin in a plastic bag and save it immediately Store in a freezer at -18 ° C. The obtained rabbit skin weight was 176 grams, and its SART activity was 0.50 iu / g. In the angiotensin production inhibitory test, the absorbance value is 0.15, and the surface has an angiotensin production inhibitory activity.
- a vaccinia virus EM-63 strain and a blue-violet rabbit were used to prepare an antigen secondary culture according to the method of Example 1.
- the injected rabbits were raised for 3 days.
- the acne is good, the color changes from ruddy to purplish red, the skin is thickened, there are leeches under the skin, and the hips are edema obvious.
- Rabbits were sacrificed by cervical dislocation, and the palate skin was completed within 15 minutes. Pack the rabbit skin in a plastic bag and store it in a freezer at -18 ° C for later use.
- the weight of the obtained rabbit skin was 230 g, and its SART activity was 0.55 iu / g.
- the absorbance value in the angiotensin production inhibitory test is 0.12, and it has an angiotensin production inhibitory activity on the surface.
- a vaccinia virus Lister strain and a New Zealand white rabbit were used to prepare an antigen secondary culture according to the method of Example 1.
- the acne is good, the color changes from ruddy to purplish red, the skin is thickened, there is edema under the skin, and the edema of the buttocks is obvious.
- Rabbits were sacrificed by cervical dislocation, and the crusts were completed within 15 minutes. Pack rabbit skins in plastic bags, Store immediately in a freezer at -18 ° C. The obtained rabbit skin weight was 310 g, and its SART activity was 0.79 iu / g.
- the absorbance value in the angiotensin production inhibitory test is 0.09, and it has an angiotensin production inhibitory activity on the surface.
- the acne is good, the color changes from ruddy to purplish red, the skin is thickened, there is edema under the skin, and the edema of the buttocks is obvious.
- Rabbits were sacrificed by pushing the neck off the white method, and skin harvesting was completed within 15 minutes. Pack the rabbit skin in a plastic bag and store it in a freezer at -18 ° C for later use. The weight of the obtained rabbit skin was 185 g, and its SART activity was 0.71iu / g. The absorbance value was 0.11 in the angiotensin production inhibitory test, and it has an angiotensin production inhibitory activity on the surface.
- an antigen secondary culture was prepared according to the method of Example 1.
- the acne is good, the color changes from ruddy to purplish red, the skin is thickened, there is edema under the skin, and the edema of the buttocks is obvious.
- Rabbits were sacrificed by cervical push-off, and the skin was finished within 15 minutes. Pack rabbit skins in plastic bags and store immediately Store in a freezer at -18 ° C. The obtained rabbit skin weight was 235 grams, and its SART activity was 0.74 iu / g.
- the absorbance value in the angiotensin production inhibition test is 0.13, and it has an angiotensin production inhibitory activity on the surface.
- Example 8 Preparation of rabbit skin ⁇ Vaccinia virus Ikeda strain and Japanese white-eared rabbit were used to prepare an anti-primary secondary culture according to the method of Example 1.
- the acne is good, the color changes from ruddy to purplish red, the skin is thickened, there is edema under the skin, and the edema of the buttocks is obvious.
- Rabbits were sacrificed by pushing the neck off the white method, and the skin was finished within 15 minutes. Pack the rabbit skin in a plastic bag and store it in a freezer at -18 ° C for later use.
- the obtained rabbit skin weight was 335 g, and its SART activity was 0.70 iu / g.
- the absorbance value in the angiotensin production inhibitory test is 0.12, and it has an angiotensin production inhibitory activity on the surface.
- an anti-primary secondary culture was prepared according to the method of Example 1.
- the acne is good, the color changes from ruddy to purplish red, the skin is thickened, there is edema under the skin, and the edema of the buttocks is obvious.
- Rabbits were sacrificed by cervical dislocation, and the crusts were completed within 15 minutes. Pack the rabbit skin in a plastic bag and save it immediately Store in a freezer at -18 ° C.
- the obtained rabbit skin weight was 336 g, and its SART activity was 0.61 iu / g.
- the absorbance value in the angiotensin production inhibitory test is 0.14, and it has an angiotensin production inhibitory activity on the surface.
- a vaccinia virus EM-63 strain and Japanese big-eared white rabbits were used to prepare an antigen secondary culture according to the method of Example 1.
- the acne is good, the color changes from ruddy to purplish red, the skin is thickened, there are leeches under the skin, and the hips are edema obvious.
- Rabbits were sacrificed by cervical dislocation, and skin harvesting was completed within 15 minutes. Pack the rabbit skin in a plastic bag and store it in a freezer at -18 ° C immediately. The obtained rabbit skin weight was 335 grams, and its SART activity was 0.66 iu / g.
- the absorbance value in the angiotensin production inhibitory test is 0.12, and it has an angiotensin production inhibitory activity on the surface.
- the rabbit skins (200 g each) of Examples 1 to 10 were cut into small pieces of about 1 square centimeter, and 4 times the weight of a 3% aqueous phenol solution was added thereto. Place it in an environment at 4 ° C for 72 hours. After the liquid becomes an emulsion, centrifuge it, remove the supernatant, and filter to obtain a brown solution A. Adjust the pH of the solution to 5.0 with 1M hydrochloric acid, and boil in water for 40 minutes. The temperature was immediately lowered to 28 ° C, followed by centrifugation, and then the supernatant was filtered to obtain solution B. The pH value of the filtrate was adjusted to 9.2 with 1M sodium hydroxide, and boiled in a water bath for 40 minutes.
- Example 1 Glutamic acid 1.64 0.85 0.70 0.80 1.54 1.20 1.40 1.12 0.98 1.03 Glycine 0.92 0.51 0.33 0.49 0.86 0.73 0.80 0.70 0.55 0.61 Alanine 0.96 0.64 0.59 0.60 0.92 0.77 0.83 0.76 0.66 0.70 Valine 0.66 0.34 0.23 0.29 0.62 0.57 0.61 0.51 0.39 0.45 Isoleucine 0.42 0.17 0.10 0.14 0.40 0.32 0.38 0.30 0.26 0.28 Leucine 0.67 0.22 0.11 0.16 0.66 0.53 0.60 0.46 '0.35 0.41 Tyrosine 0.83 0.30 0.25 0.20 0.77 0.61 0.69 0.52 0.36 0.44 Phenylalanine 0.55 0.26 0.24 0.25 0.53 0.42 0.48 0.34 0.30 0.33 Lysine 0.47 0.1 1 0.09 0.10 0.45 0.39 0.34 0.34 0.19 0.26 Histidine 0.64 0.24 0.18 0.21 0.57 0.43 0.53 0.41 0.31 0.
- the rabbit skin of the present invention has a SART activity greater than or equal to 0.5 iu / g, and has an angiotensin production inhibitory activity.
- an active preparation containing a variety of amino acids and nucleic acids can be prepared from the rabbit skin, wherein the amino acids include glutamic acid, glycine, and alanine. , Valine, isoleucine, leucine, tyrosine, phenylalanine, lysine, histidine, aspartic acid, threonine, serine; nucleic acids including uric acid , Uracil, hypoxanthine, xanthine, thymine.
- excipients can be distilled water for injection, physiological saline, vegetable oil for injection, glucose injection, propylene glycol, polyethylene glycol, etc., and various stabilizers, emulsifiers, etc .; in tablets, capsules, and granules
- excipients may be excipients such as starch, lactose, mannitol, crystalline cellulose, acacia, corn starch, gelatin, polyethylene, polyvinyl alcohol, polyvinylpyrrolidone, and other binding agents, carboxymethyl cellulose, polymer Ethylene glycol, potato starch disintegrant, lubricants such as talc and magnesium stearate, wetting agents such as glycerin, etc.
- the excipients can be distilled water for injection, physiological saline, vegetable oil for injection, glucose injection, propylene glycol, polyethylene glycol, etc., and various stabilizers, emulsifiers, etc .; in tablets, capsules
- the medicine prepared from the rabbit skin of the present invention can effectively promote macrophage activation, significantly inhibit the 48-hour homologous PCA response caused by the IgE antibody of a mouse that is a type I allergy reaction model, and can inhibit The model anti-complement activity of type II allergies is linear with its dose. From this, it can be seen that the medicine prepared from the rabbit skin of the present invention has the effect of suppressing inflammation related to the immune function, and can improve the immune function.
- the medicine prepared from the rabbit skin of the present invention also has anti-allergic, anti-ulcer, and sedative effects.
- the medicine prepared from the rabbit skin of the present invention was administered intraperitoneally to rats for 28 consecutive days, and no death occurred in any group.
- Urine test, ophthalmological test, blood chemistry test, histopathological examination, and anatomy all showed no existence. Changes due to administration of analgesics of the invention. These indicate that the analgesics of the present invention are very toxic.
- the active preparation can be combined with food additives and nutrients to make a health product.
- the food additives and nutrients include various vitamins and various flavoring agents. From this
- the health product prepared by the rabbit skin has the functions of enhancing immune function, alleviating pain, anti-allergic and anti-nervous.
- the angiotensin production inhibitory activity referred to herein is determined by the following method: Rabbit skin is cut into small pieces of about 1 square centimeter, and 4 times the weight of a 3% aqueous phenol solution is added thereto. It was placed in a 4 ⁇ environment for 72 hours. The liquid became an emulsion and centrifuged. The supernatant was taken out and filtered to obtain a brown solution A. The pH of the solution was adjusted to 5.0 with 1M hydrochloric acid, and the solution was boiled in a water bath for 40 minutes. The temperature was immediately reduced.
- the SART activity of the above solution was adjusted to 1.2 iu / ml by evaporation and dilution with distilled water, 10 ml of the solution was taken, desalted under the condition of a final conductivity of 10 s / cm, and dried under reduced pressure, and 0.25 M sodium chloride was added. 1.5 ml of the solution to obtain the test solution.
- 0.2 ml of a 0.25 M sodium chloride solution as a control solution, the following treatment was performed in parallel with 0.2 ml of the test solution. Inject 0.5ml of the diluted human plasma into the test solution and the control solution, and leave them at the freezing point for 5 minutes, add 0.25ml of white clay suspension, and leave them at the freezing point for 20 minutes.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Polymers & Plastics (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Anesthesiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03770855A EP1557171A4 (en) | 2002-10-31 | 2003-10-30 | RABBIT WITH A BIOLOGICAL ACTIVE SUBSTANCE AND ITS USE |
NZ540428A NZ540428A (en) | 2002-10-31 | 2003-10-30 | Rabbit skin comprising biological active substance and its use |
US10/532,687 US20060051375A1 (en) | 2002-10-31 | 2003-10-30 | Rabbit skin comprising biological active substances and its use |
AU2003280918A AU2003280918A1 (en) | 2002-10-31 | 2003-10-30 | Rabbit skin comprising biological active substance and its use |
US12/880,856 US20110003009A1 (en) | 2002-10-31 | 2010-09-13 | Process for obtaining a rabbit skin comprising biological active substances |
US13/777,637 US8900639B2 (en) | 2002-10-31 | 2013-02-26 | Process for obtaining a rabbit skin comprising biological active substances |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB021459754A CN1207005C (zh) | 2002-10-31 | 2002-10-31 | 含生物活性物质的兔皮和其用途 |
CN02145975.4 | 2012-10-31 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10532687 A-371-Of-International | 2003-10-30 | ||
US12/880,856 Continuation US20110003009A1 (en) | 2002-10-31 | 2010-09-13 | Process for obtaining a rabbit skin comprising biological active substances |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004060381A1 true WO2004060381A1 (fr) | 2004-07-22 |
WO2004060381A8 WO2004060381A8 (en) | 2006-08-10 |
Family
ID=32686811
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2003/000923 WO2004060381A1 (fr) | 2002-10-31 | 2003-10-30 | Peau de lapin comprenant une substance bioactive et son utilisation |
Country Status (7)
Country | Link |
---|---|
US (3) | US20060051375A1 (zh) |
EP (1) | EP1557171A4 (zh) |
KR (2) | KR20050072768A (zh) |
CN (1) | CN1207005C (zh) |
AU (1) | AU2003280918A1 (zh) |
NZ (1) | NZ540428A (zh) |
WO (1) | WO2004060381A1 (zh) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1669082A1 (en) * | 2004-12-01 | 2006-06-14 | Nippon Zoki Pharmaceutical Co., Ltd. | Dried extract from inflammatory rabbit skin inoculated with vaccinia virus and process for its manufacture |
WO2014057995A1 (ja) | 2012-10-10 | 2014-04-17 | 日本臓器製薬株式会社 | 抽出物及び該抽出物を含有する製剤 |
JP2014077779A (ja) * | 2013-04-19 | 2014-05-01 | Nippon Zoki Pharmaceut Co Ltd | 抽出物及び製剤 |
WO2014178394A1 (ja) | 2013-04-30 | 2014-11-06 | 日本臓器製薬株式会社 | 抽出物及び該抽出物を含有する製剤 |
US8900639B2 (en) | 2002-10-31 | 2014-12-02 | Vanworld Pharmaceutical (Rugao) Company Limited | Process for obtaining a rabbit skin comprising biological active substances |
CN107635570A (zh) * | 2015-05-29 | 2018-01-26 | 日本脏器制药株式会社 | 多能性干细胞迁移促进剂 |
WO2020211009A1 (zh) | 2019-04-17 | 2020-10-22 | 诺希生物药物开发有限公司 | 痘苗病毒致炎兔皮提取物治疗造血系统损伤的用途 |
CN111944042A (zh) * | 2020-09-07 | 2020-11-17 | 威世药业(如皋)有限公司 | 一种蛋白-a抗原的制备工艺 |
WO2020248240A1 (zh) | 2019-06-14 | 2020-12-17 | 俊熙有限公司 | 痘苗病毒致炎兔皮提取物治疗癌症的用途 |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7148012B2 (en) * | 2002-10-31 | 2006-12-12 | Nippon Zoki Pharmaceutical Co., Ltd. | Therapeutic agent for fibromyalgia |
CN1613305B (zh) * | 2004-12-06 | 2011-01-12 | 威世药业(如皋)有限公司 | 一种从含新型活性物质的兔皮中提取的活性制剂 |
CN101732348B (zh) | 2008-11-11 | 2015-01-14 | 威世药业(如皋)有限公司 | 牛痘疫苗致炎兔皮提取物在制备急性脑血管疾病治疗药物中的用途 |
KR101853254B1 (ko) | 2012-05-25 | 2018-05-02 | 웰 리소시스 리미티드 | 펩타이드 및 그의 용도 |
JP6757897B2 (ja) | 2016-02-24 | 2020-09-23 | 国立大学法人大阪大学 | 試験方法 |
CN105663166B (zh) * | 2016-03-02 | 2020-04-17 | 中国人民解放军疾病预防控制所 | 特异性抗天花病毒感染模型毒株的生物活性制剂及应用 |
CN109512838B (zh) * | 2017-09-15 | 2022-05-10 | 天津小西生物医药科技有限公司 | 一种兔皮提取物及其制备方法和用途 |
RU2707948C1 (ru) * | 2019-09-02 | 2019-12-02 | Виктор Александрович Сисев | Фармацевтическая композиция для парентерального капельного введения (варианты) |
CN111904981A (zh) * | 2020-09-07 | 2020-11-10 | 威世药业(如皋)有限公司 | 一种痘苗病毒致炎兔皮生产方法 |
CN111956669A (zh) * | 2020-09-07 | 2020-11-20 | 威世药业(如皋)有限公司 | 一种牛痘疫苗致炎兔皮提取物注射液制造工艺 |
CN115212235A (zh) * | 2022-07-25 | 2022-10-21 | 威世药业(如皋)有限公司 | 一种稀释后痘苗病毒致炎兔皮生产方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5057324A (en) * | 1987-07-23 | 1991-10-15 | Nippon Zoki Pharmaceutical Co., Ltd. | Kallikrein inhibitor substance, a process for preparation and pharmaceutical compositions thereof |
CN1055249C (zh) * | 1998-07-15 | 2000-08-09 | 沈继平 | 一种镇痛药和其制造方法 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3455784A (en) * | 1966-03-11 | 1969-07-15 | American Home Prod | Control of enzyme activity in frozen systems |
US3949073A (en) * | 1974-11-18 | 1976-04-06 | The Board Of Trustees Of Leland Stanford Junior University | Process for augmenting connective mammalian tissue with in situ polymerizable native collagen solution |
JPS53101515A (en) | 1977-02-17 | 1978-09-05 | Nippon Zoki Pharmaceutical Co | Medicine having anodyne * sedative and antiallergic activity and production thereof |
JPS578741A (en) * | 1980-06-17 | 1982-01-18 | Eisai Co Ltd | Quality improvement of animal fur |
FR2564320B1 (fr) | 1984-05-18 | 1986-10-17 | Pasteur Institut | Procede de production de vaccin antirabique sur des cultures de lignees de cellules non tumorigenes de lapin, vaccin antirabique obtenu par ce procede et nouvelles lignees cellulaires utilisables pour la production dudit vaccin |
JPS6339572A (ja) * | 1986-08-05 | 1988-02-20 | 株式会社チノー | 葉たばこ乾燥装置 |
US4798171A (en) * | 1987-07-09 | 1989-01-17 | Nu Aire, Inc. | Animal isolator |
US4985254A (en) * | 1987-11-06 | 1991-01-15 | Nippon Zoki Pharmaceutical Co., Ltd. | Method of treating ischemic diseases |
DE68909100T2 (de) * | 1988-04-30 | 1994-01-13 | Nippon Zoki Pharmaceutical Co | Physiologisch wirkende Substanzen, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen davon. |
JP2539665B2 (ja) * | 1988-06-20 | 1996-10-02 | 日本臓器製薬株式会社 | 神経疾患治療剤 |
US5225331A (en) * | 1991-04-25 | 1993-07-06 | National Research Council Of Canada | Immunoassay for detecting group b streptococcus |
JP2594222B2 (ja) | 1993-09-28 | 1997-03-26 | 日本臓器製薬株式会社 | 新規生理活性物質−kf |
US6019988A (en) * | 1996-11-18 | 2000-02-01 | Bristol-Myers Squibb Company | Methods and compositions for enhancing skin permeation of drugs using permeation enhancers, when drugs and/or permeation enhancers are unstable in combination during long-term storage |
JP4033936B2 (ja) * | 1997-01-08 | 2008-01-16 | 日本臓器製薬株式会社 | 一酸化窒素産生抑制剤 |
JPH1180005A (ja) * | 1997-09-12 | 1999-03-23 | Nippon Zoki Pharmaceut Co Ltd | 骨粗鬆症治療剤 |
JPH11139977A (ja) * | 1997-11-07 | 1999-05-25 | Nippon Zoki Pharmaceut Co Ltd | Nef作用抑制剤 |
US5960635A (en) * | 1998-03-03 | 1999-10-05 | Dakhil; Farouk | Air conditioning apparatus using liquid nitrogen |
KR19990083516A (ko) * | 1998-04-27 | 1999-11-25 | 고니시 진우에몬 | 허혈성질환치료제 |
CN100425692C (zh) | 1998-06-02 | 2008-10-15 | 株式会社富吉摩托普拉泽兹 | 含有高质量生理活性的家兔发痘组织的制造方法 |
KR20000076874A (ko) * | 1999-03-19 | 2000-12-26 | 고니시 진우에몬 | 케모카인 생산 촉진제 |
JP4612924B2 (ja) * | 1999-08-20 | 2011-01-12 | 藤本製薬株式会社 | サイトカイン調節剤 |
JP2001058949A (ja) * | 1999-08-20 | 2001-03-06 | Fujimoto Brothers:Kk | 抗ショック剤 |
UA78738C2 (en) * | 2001-12-10 | 2007-04-25 | Bavarian Nordic As | Composition containing cowpox virus and method for its preparation |
CN1207005C (zh) | 2002-10-31 | 2005-06-22 | 威世药业(如皋)有限公司 | 含生物活性物质的兔皮和其用途 |
-
2002
- 2002-10-31 CN CNB021459754A patent/CN1207005C/zh not_active Ceased
-
2003
- 2003-10-30 KR KR1020057006991A patent/KR20050072768A/ko active Search and Examination
- 2003-10-30 NZ NZ540428A patent/NZ540428A/en not_active IP Right Cessation
- 2003-10-30 US US10/532,687 patent/US20060051375A1/en not_active Abandoned
- 2003-10-30 WO PCT/CN2003/000923 patent/WO2004060381A1/zh not_active Application Discontinuation
- 2003-10-30 EP EP03770855A patent/EP1557171A4/en not_active Ceased
- 2003-10-30 AU AU2003280918A patent/AU2003280918A1/en not_active Abandoned
- 2003-10-30 KR KR1020087008934A patent/KR20080048536A/ko active Search and Examination
-
2010
- 2010-09-13 US US12/880,856 patent/US20110003009A1/en not_active Abandoned
-
2013
- 2013-02-26 US US13/777,637 patent/US8900639B2/en not_active Expired - Lifetime
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5057324A (en) * | 1987-07-23 | 1991-10-15 | Nippon Zoki Pharmaceutical Co., Ltd. | Kallikrein inhibitor substance, a process for preparation and pharmaceutical compositions thereof |
CN1055249C (zh) * | 1998-07-15 | 2000-08-09 | 沈继平 | 一种镇痛药和其制造方法 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1557171A4 * |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8900639B2 (en) | 2002-10-31 | 2014-12-02 | Vanworld Pharmaceutical (Rugao) Company Limited | Process for obtaining a rabbit skin comprising biological active substances |
AU2005235903B2 (en) * | 2004-12-01 | 2011-08-25 | Nippon Zoki Pharmaceutical Co., Ltd | A dried product and a process for manufacturing the product |
KR101307999B1 (ko) | 2004-12-01 | 2013-09-12 | 니폰 조키 세야쿠 가부시키가이샤 | 건조물 및 그 제조방법 |
US8568789B2 (en) | 2004-12-01 | 2013-10-29 | Nippon Zoki Pharmaceutical Co., Ltd. | Dried product and a process for manufacturing the product |
EP1669082A1 (en) * | 2004-12-01 | 2006-06-14 | Nippon Zoki Pharmaceutical Co., Ltd. | Dried extract from inflammatory rabbit skin inoculated with vaccinia virus and process for its manufacture |
KR20150064036A (ko) | 2012-10-10 | 2015-06-10 | 니폰 조키 세야쿠 가부시키가이샤 | 추출물 및 그 추출물을 함유하는 제제 |
WO2014057995A1 (ja) | 2012-10-10 | 2014-04-17 | 日本臓器製薬株式会社 | 抽出物及び該抽出物を含有する製剤 |
US11529374B2 (en) | 2012-10-10 | 2022-12-20 | Nippon Zoki Pharmaceutical Co., Ltd. | Extract and formulation including extract |
JP2014077779A (ja) * | 2013-04-19 | 2014-05-01 | Nippon Zoki Pharmaceut Co Ltd | 抽出物及び製剤 |
WO2014178394A1 (ja) | 2013-04-30 | 2014-11-06 | 日本臓器製薬株式会社 | 抽出物及び該抽出物を含有する製剤 |
KR20160002767A (ko) | 2013-04-30 | 2016-01-08 | 니폰 조키 세야쿠 가부시키가이샤 | 추출물 및 그 추출물을 함유하는 제제 |
US9884077B2 (en) | 2013-04-30 | 2018-02-06 | Nippon Zoki Pharmaceutical Co., Ltd. | Extract and preparation containing said extract |
CN107635570A (zh) * | 2015-05-29 | 2018-01-26 | 日本脏器制药株式会社 | 多能性干细胞迁移促进剂 |
CN107635570B (zh) * | 2015-05-29 | 2019-03-19 | 日本脏器制药株式会社 | 多能性干细胞迁移促进剂 |
WO2020211009A1 (zh) | 2019-04-17 | 2020-10-22 | 诺希生物药物开发有限公司 | 痘苗病毒致炎兔皮提取物治疗造血系统损伤的用途 |
US12090176B2 (en) | 2019-04-17 | 2024-09-17 | Nexus Bio-Drug Development Limited | Use of extract from rabbit skin inflamed by vaccinia virus in treating hematopoietic system damage |
WO2020248240A1 (zh) | 2019-06-14 | 2020-12-17 | 俊熙有限公司 | 痘苗病毒致炎兔皮提取物治疗癌症的用途 |
CN111944042A (zh) * | 2020-09-07 | 2020-11-17 | 威世药业(如皋)有限公司 | 一种蛋白-a抗原的制备工艺 |
Also Published As
Publication number | Publication date |
---|---|
KR20050072768A (ko) | 2005-07-12 |
AU2003280918A1 (en) | 2004-07-29 |
US8900639B2 (en) | 2014-12-02 |
KR20080048536A (ko) | 2008-06-02 |
EP1557171A4 (en) | 2006-08-09 |
US20060051375A1 (en) | 2006-03-09 |
CN1207005C (zh) | 2005-06-22 |
US20110003009A1 (en) | 2011-01-06 |
US20130183386A1 (en) | 2013-07-18 |
EP1557171A1 (en) | 2005-07-27 |
WO2004060381A8 (en) | 2006-08-10 |
CN1493302A (zh) | 2004-05-05 |
AU2003280918A8 (en) | 2004-07-29 |
NZ540428A (en) | 2007-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004060381A1 (fr) | Peau de lapin comprenant une substance bioactive et son utilisation | |
WO2015176558A1 (zh) | 一种天然维生素c和鱼鳞胶原蛋白肽的组合物及其制备方法 | |
CN108785328A (zh) | 预防或治疗实体肿瘤和血液系统肿瘤的方法及所用熊胆粉 | |
CN108635375A (zh) | 预防或治疗肝病和肝纤维化及改善肝功能的熊胆粉及用途 | |
CN108578433A (zh) | 用于预防或治疗胆结石症胆囊炎和改善胆囊功能的熊胆粉 | |
CN1055249C (zh) | 一种镇痛药和其制造方法 | |
KR100699790B1 (ko) | 댕댕이나무 추출물을 포함하는 간 질환 예방 및 치료효과를 가지는 약제학적 조성물 | |
CN1613305B (zh) | 一种从含新型活性物质的兔皮中提取的活性制剂 | |
CN104873796A (zh) | 一种接种家兔用猪瘟病毒辅助液及其制备方法 | |
US7780992B2 (en) | Antiviral medicament | |
CN101647813A (zh) | 一种动物药的仿生酶解产物及其用途 | |
CN112516183B (zh) | 一种针对外伤具有修复作用的提取物制备方法及应用 | |
CN113056279B (zh) | 美洲大蠊提取物、其制剂以及它们的制备方法和应用 | |
CN108187032A (zh) | 虫草胶原蛋白肽片 | |
CN107056959A (zh) | 菊芋中抗hsv‑1、rsv、ev‑71成分及制备 | |
CN105995971A (zh) | 一种促进糖尿病康复的营养流食及其制备方法 | |
CN106798916A (zh) | 一种治疗hpv感染的组合物及其应用 | |
CN109745548A (zh) | 一种百日咳毒素在治疗脑梗死中的应用 | |
CN106822877A (zh) | 一种治疗hpv感染的组合物及其应用 | |
CN107929372A (zh) | 治疗甲癣的中药组合物及其制备方法和用途 | |
de Vries et al. | Clinical aspects of elapid bite | |
CN104940237B (zh) | 一种鳄鱼血去蛋白提取物及其提取方法和应用 | |
CN106074847A (zh) | 一种治疗白血病并发弥散性血管内凝血的药物组合物 | |
TW201628635A (zh) | 用以改善糖尿病視網膜病變之中草藥組合物及其用途 | |
KR20150078924A (ko) | 작약 추출물을 유효 성분으로 포함하는 인플라마좀 매개 염증성 질환 예방, 개선용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1200500378 Country of ref document: VN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003770855 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 306/MUMNP/2005 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057006991 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1-2005-500764 Country of ref document: PH |
|
ENP | Entry into the national phase |
Ref document number: 2006051375 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10532687 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 540428 Country of ref document: NZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057006991 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2003770855 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10532687 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: JP |